A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
Public ClinicalTrials.gov record NCT07406360. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).
Study identification
- NCT ID
- NCT07406360
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,209 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 15 Months to 6 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 10, 2026
- Primary completion
- Feb 27, 2028
- Completion
- Jul 19, 2028
- Last update posted
- Jul 7, 2026
2026 – 2028
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35235 | Recruiting |
| GSK Investigational Site | Walnut Creek | California | 94598 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33142 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33182 | Recruiting |
| GSK Investigational Site | Atlanta | Georgia | 30310 | Recruiting |
| GSK Investigational Site | Chicago | Illinois | 60621 | Recruiting |
| GSK Investigational Site | Farmington Hills | Michigan | 48334 | Recruiting |
| GSK Investigational Site | Dayton | Ohio | 45406 | Recruiting |
| GSK Investigational Site | Simpsonville | South Carolina | 29680 | Recruiting |
| GSK Investigational Site | Spartanburg | South Carolina | 29301 | Recruiting |
| GSK Investigational Site | Frisco | Texas | 75033 | Recruiting |
| GSK Investigational Site | Houston | Texas | 77065 | Recruiting |
| GSK Investigational Site | Houston | Texas | 77077 | Recruiting |
| GSK Investigational Site | Port Lavaca | Texas | 77979 | Recruiting |
| GSK Investigational Site | Richmond | Texas | 77469 | Recruiting |
| GSK Investigational Site | Provo | Utah | 84604 | Recruiting |
| GSK Investigational Site | Richmond | Virginia | 23294 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07406360, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07406360 live on ClinicalTrials.gov.